ScreenerHero
WGSGeneDx Holdings Corp. Class A Common Stock
NAS · US · Technology · Diagnostics & Research · genedx.com
81.36USD+2.14%Mkt Cap: 2.38B $P/E: —

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and inf…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group AG
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1

Key Statistics

Company
Market Cap2.38B $
Enterprise Value2.50B $
Revenue (TTM)454.43M $
Gross Profit298.17M $
Net Income (TTM)-21.02M $
Revenue/Share15.55 USD
Last Price81.36 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.3K
CountryUS
SectorTechnology
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)70.63
PEG—
EV/EBITDA-74.10
EV/Revenue5.49
P/S5.42
P/B9.64
EPS (TTM)-3.76
EPS (Forward)1.17
52W Range
32.2135% of range170.87
52W High170.87 USD
52W Low32.21 USD
Profitability
Gross Margin69.74%
Oper. Margin-15.21%
EBITDA Margin-7.41%
Profit Margin-4.92%
ROE-6.82%
ROA-4.01%
Growth
Revenue Growth11.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF33.28M $
CapEx (TTM)19.02M $
FCF Margin-10.45%
FCF Yield-2.00%
Net Debt34.85M $
Net Debt/EBITDA-1.03
Balance Sheet
Debt/Equity0.37
Current Ratio3.30
Quick Ratio2.90
Book Value/Sh8.566 USD
Cash/Share4.445 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:33
Split DateMay 4, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)90.44 USD
Upside (mean)+11.2%
Target Range74.00 USD – 103.00 USD
$74.00+11.2% to mean$103.00
# Analysts9
Ownership
Shares Out.29.82M
Float19.09M
Insiders12.25%
Institutions107.54%
Short Interest
Short Ratio8.5d
Short % Float37.54%
Short % Out.19.61%
Shares Short5.85M
Short (prev mo.)5.94M
Technical
SMA 5067.11 (+21.2%)
SMA 20087.54 (-7.1%)
Beta1.98
S&P 52W Chg18.16%
Avg Vol (30d)752.40K
Avg Vol (10d)603.16K
Technical Indicators
RSI (14)63.9
MACD4.4857
MACD Signal3.7885
MACD Hist.+0.6972
BB Upper86.26 USD
BB Middle70.84 USD
BB Lower55.42 USD
BB Width43.53%
ATR (14)4.909 USD
Vol Ratio (20d)0.85x